It’s Time To Focus On The Long Run With ACADIA Pharmaceuticals Inc. (ACAD) stock

The closing price of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was $20.38 for the day, up 5.00% from the previous closing price of $19.41. In other words, the price has increased by $+0.97 from its previous closing price. On the day, 3425721 shares were traded. ACAD stock price reached its highest trading level at $20.78 during the session, while it also had its lowest trading level at $19.76.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



Our analysis of ACAD’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.00 and its Current Ratio is at 4.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

On November 04, 2022, Goldman Downgraded its rating to Sell which previously was Neutral and also lowered its target price recommendation from $15 to $12.

On November 01, 2022, Loop Capital started tracking the stock assigning a Hold rating and target price of $17.Loop Capital initiated its Hold rating on November 01, 2022, with a $17 target price.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 24 when DAVIS STEPHEN sold 3,851 shares for $18.78 per share. The transaction valued at 72,322 led to the insider holds 91,727 shares of the business.

KIM AUSTIN D. sold 803 shares of ACAD for $15,080 on Feb 24. The EVP,General Counsel, Secretary now owns 20,108 shares after completing the transaction at $18.78 per share. On Feb 24, another insider, Schneyer Mark C., who serves as the EVP, Chief Financial Officer of the company, sold 577 shares for $18.78 each. As a result, the insider received 10,836 and left with 4,118 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 6.44 while its Price-to-Book (P/B) ratio in mrq is 8.25.

Stock Price History:

Over the past 52 weeks, ACAD has reached a high of $28.06, while it has fallen to a 52-week low of $12.24. The 50-Day Moving Average of the stock is 18.97, while the 200-Day Moving Average is calculated to be 16.73.

Shares Statistics:

ACAD traded an average of 1.43M shares per day over the past three months and 2.5M shares per day over the past ten days. A total of 161.99M shares are outstanding, with a floating share count of 161.70M. Insiders hold about 0.10% of the company’s shares, while institutions hold 94.90% stake in the company. Shares short for ACAD as of Jan 30, 2023 were 8.1M with a Short Ratio of 8.04M, compared to 8.39M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 5.00% and a Short% of Float of 6.77%.

Earnings Estimates

The firm’s stock currently is rated by 21 analysts. On average, analysts expect EPS of -$0.24 for the current quarter, with a high estimate of -$0.15 and a low estimate of -$0.37, while EPS last year was -$0.27. The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.25 and low estimates of -$0.47.

Analysts are recommending an EPS of between -$1.13 and -$1.38 for the fiscal current year, implying an average EPS of -$1.31. EPS for the following year is -$0.88, with 20 analysts recommending between -$0.35 and -$1.46.

Revenue Estimates

It is expected that $90B in revenue will be generated in the current quarter, according to 18 analysts. It ranges from a high estimate of $139M to a low estimate of $129.7M. As of the current estimate, ACADIA Pharmaceuticals Inc.’s year-ago sales were $130.76M, an estimated increase of 2.60% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $122.25M, an increase of 5.90% over than the figure of $2.60% in the same quarter last year. There is a high estimate of $127.47M for the next quarter, whereas the lowest estimate is $118M.

A total of 21 analysts have provided revenue estimates for ACAD’s current fiscal year. The highest revenue estimate was $519.7M, while the lowest revenue estimate was $510.4M, resulting in an average revenue estimate of $514.89M. In the same quarter a year ago, actual revenue was $484.14M, up 6.40% from the average estimate. Based on 20 analysts’ estimates, the company’s revenue will be $570.07M in the next fiscal year. The high estimate is $638.67M and the low estimate is $527.4M. The average revenue growth estimate for next year is up 10.70% from the average revenue estimate for this year.